



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

**Reagent:** Panel of HIV-1 Subtype C Env Clones

**Catalog Number:** 11326

**Lot Number:** 060776

**Release Category:** C

**Provided:** 1 vial of plasmid DNA in TE buffer.

**Cloning Site:** The HIV-1 env/rev cassette was either directly inserted (cat# 11306, 11307, 11308, 11316 and 11317) or TA cloned (all others) into the cloning site of the expression vector in the correct orientation with the CMV promoter.

**Description:** This clade C reference panel was designed for use as Env-pseudotyped viruses to facilitate standardized Tier 2/3 assessments of HIV-1-specific neutralizing antibodies (Mascola JR. et al. *J Virology* **79**(16):10103, 2005). When co-transfected with an env-deleted backbone plasmid (e.g. pSG3<sup>Δenv</sup>, cat# 11051) in 293T cells, these plasmids produce Env-pseudotyped viruses that are capable of a single round of infection in TZM-bl cells (cat# 8129). The TZM-bl cell line is not part of this panel; therefore it should be separately ordered. The Env-pseudotyped viruses exhibit a neutralization phenotype that is typical of most primary HIV-1 isolates. Notably, no clone is unusually sensitive or resistant to neutralization. The gp160 genes were cloned from sexually acquired, acute/early infections and comprise a wide spectrum of genetic, antigenic and geographic diversity within subtype C (Li M, et al. manuscript in preparation). These clones use CCR5 as co-receptor. Plasmid sequence information is available upon request.

[See Clade C HIV-1 reference panel of Env clones](#)

**Special Characteristics:** [Click here to obtain the additional form required for this reagent.](#)

**Recommended Storage:** -80°C

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**Contributor:** See table below.

**References:** <sup>1</sup>Li, M. et al. in preparation. <sup>2</sup>Derdeyn C.A., Decker J.M., Bibollet-Ruche F., Mokili J. L., Muldoon M., Denham S.A., Heil M.L., Lee J.Y., Kasolo F., Musonda R., Hahn B.H., Shaw G.M., Korber B. T., Allen S. and Hunter E. (2004). Envelope-Constrained, Neutralization-Sensitive HIV-1 Following Heterosexual Transmission. *Science* **303**(5666):2019-2022, 2004. <sup>3</sup>Williamson C., Morris L., Maughan M.F., Ping L.H., Dryga S.A., Thomas R., Reap E.A., Cilliers T., van Harmelen J., Pascual A., Ramjee G., Gray G., Johnston R., Abdool-Karim S., Swanstrom R. Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. *AIDS Res Hum Retro.*, **19**: 133-144, 2003.

**NOTE:** **These clones are available as a panel but they can also be ordered individually by catalog number. Additional information for each clone can be found by searching for the individual catalog numbers.**

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH from (contributors): (name of clone)." Also include the references cited above in any publications.

The clone Du422 (#11308) is submitted to the NIH AIDS Reagent Program under release category C. All requestors of this clone must complete the "SAAVI Addendum for Category C Clone Du422" form before the reagent can be released. Queries can be directed to The Intellectual Property Manager, UCT Innovation, University of Cape Town, Private Bag, Rondebosch 7701, South Africa, Tel: +27-21-650-2425, Fax: +27-21-650-5778.

**Scientists at for-profit institutions or who intend commercial use of this reagent must contact Hayes A. Lowe, J.D., UAB Research Foundation, The Office of Intellectual Property Management, AB 1120G, 1530 3rd Ave. S, Birmingham AL 35294-0111, Tel: 205-975-0843 Fax: 205-934-5427, email: [halowe@uab.edu](mailto:halowe@uab.edu), before the reagent can be released.**

**Research Chart:**

| Catalog # | Provided     | Conc.     | Antibiotics Resistance |
|-----------|--------------|-----------|------------------------|
| 11306     | 7 µg (26ml)  | 264 µg/ml | Ampicillin & Neomycin  |
| 11307     | 9 µg (26ml)  | 341 µg/ml | Ampicillin & Neomycin  |
| 11308     | 10 µg (26ml) | 401 µg/ml | Ampicillin & Neomycin  |
| 11309     | 10 µg (25ml) | 403 µg/ml | Ampicillin             |
| 11310     | 11 µg (20ml) | 537 µg/ml | Ampicillin             |
| 11311     | 12 µg (25ml) | 479 µg/ml | Ampicillin             |
| 11312     | 10 µg (20ml) | 530 µg/ml | Ampicillin             |
| 11313     | 12 µg (30ml) | 390 µg/ml | Ampicillin             |
| 11314     | 10 µg (33ml) | 306 µg/ml | Ampicillin             |
| 11315     | 9 µg (26ml)  | 346 µg/ml | Ampicillin             |
| 11316     | 9 µg (26ml)  | 338 µg/ml | Ampicillin             |
| 11317     | 7 µg (26ml)  | 267 µg/ml | Ampicillin             |

**Required Form:** SAAVI.pdf

**Last Updated:** April 28, 2015

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.